Pain therapy | What pain does osteoporosis cause?

Pain therapy

For the long-term treatment of pain it is of course essential to treat the cause – in this case osteoporosis – in a targeted manner (see below). In the short term, common painkillers such as ibuprofen or diclofenac provide relief for mild to moderate pain. However, these should not be taken over a longer period of time (no more than approx.

10 days per month), as they can cause unpleasant side effects (stomach aches up to ulcers; kidney damage). So if the pain is so intense and constant that the above-mentioned remedies cannot be further exhausted, a systematic step-by-step therapy should be drawn up with a doctor, which additionally includes opioid-containing painkillers such as tilidine or tramadol. For less severe pain or as a supplement to drug therapy, physiotherapy and physiotherapy are also suitable.

They help to relieve tension and build up muscles to relieve the skeleton. In some cases, psychological support can also be useful. Surgical procedures are the last and most profound therapy option. Here, for example, a collapsed vertebral body can be stabilized by injecting a rapidly hardening plastic.

Osteoporosis therapy

The treatment of osteoporosis aims at slowing down bone resorption or remineralization of bone substance. An adequate supply of calcium, which is an important component of bone substance, and vitamin D is essential for this. This vitamin is an essential regulator of bone metabolism and is produced in the body in the kidney and skin, among other places.

Therefore, kidney damage as well as a lack of UV radiation on the skin can lead to a vitamin D deficiency. Since both substances are of such great importance for bone metabolism, there are practical combination preparations containing both substances. In addition to these basic measures there are further active substances. These include above all the bisphosphonates (e.g. alendronate) or raloxifene, which is mainly used in women after the menopause. Other alternatives are the relatively new denosumab, the parathyroid hormone or strontium ranelate.